Endocrine resistance in breast cancer

References

• Gruber CJ, Tschugguel W, Schneeberger C, Huber JC. Production and actions of estrogens. N Engl J Med 2002;346:340–52
   PubMed Web of Science ®Google Scholar
• Lin CY, Ström A, Vega VB, et al. Discovery of estrogen receptor alpha target genes and response elements in breast tumor cells. Genome Biol 2004;5:R66
   PubMedGoogle Scholar
• Lawson JS, Field AS, Tran DD, et al. Breast cancer incidence and estrogen receptor alpha in normal mammary tissue – an epidemiologic study among Japanese women in Japan and Hawaii. Int J Cancer 2002; 97:685–7
   PubMed Web of Science ®Google Scholar
• Boswell KA, Wang X, Shah MV, Aapro MS. Disease burden and treatment outcomes in second-line therapy of patients with estrogen receptor-positive (ER+) advanced breast cancer: a review of the literature. Breast 2012;21:701–6
   PubMed Web of Science ®Google Scholar
• Ma CX, Sanchez CG, Ellis MJ. Predicting endocrine therapy responsiveness in breast cancer. Oncology 2009;23:133–42
   PubMed Web of Science ®Google Scholar
• Osborne CK, Fuqua SA. Mechanisms of tamoxifen resistance. Breast Cancer Res Treat 1994;32:49–55
   PubMed Web of Science ®Google Scholar
• Bergamaschi A, Katzenellenbogen BS. Tamoxifen downregulation of miR-451 increases 14-3-3f and promotes breast cancer cell survival and endocrine resistance. Oncogene 2012;31:39–47
   PubMed Web of Science ®Google Scholar
• Tomlinson DC, Knowles MA, Speirs V. Mechanisms of FGFR3 actions in endocrine resistant breast cancer. Int J Cancer 2012; 130:2857–66
   PubMed Web of Science ®Google Scholar
• Roy R, Wewer UM, Zurakowski D, Pories SE, Moses MA. ADAM 12 cleaves extracellular matrix proteins and correlates with cancer status and stage. J Biol Chem 2004;279:51323–30
   PubMed Web of Science ®Google Scholar
• Roy R, Moses MA. ADAM12 induces estrogen-independence in breast cancer cells. Breast Cancer Res Treat 2012;131: 731–41
   PubMed Web of Science ®Google Scholar
• Pontiggia O, Sampayo R, Raffo D, et al. The tumor microenvironment modulates tamoxifen resistance in breast cancer: a role for soluble stromal factors and fibronectin through b1 integrin. Breast Cancer Res Treat 2012;133:459–71
   PubMed Web of Science ®Google Scholar
• Cortez V, Mann M, Tekmal S, et al. Targeting the PELP1-KDM1 axis as a potential therapeutic strategy for breast cancer. Breast Cancer Res 2012;14:R108
   PubMed Web of Science ®Google Scholar
• Pietras RJ, Arboleda J, Reese DM, et al. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 1995;10:2435–46
   PubMed Web of Science ®Google Scholar
• Shou J, Massarweh S, Osborne CK, et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 2004;96:926–35
   PubMed Web of Science ®Google Scholar
• Dowsett M. Overexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer. Endocr Relat Cancer 2001;8:191–5
   PubMed Web of Science ®Google Scholar
• Kumar R, Mandal M, Lipton A, Harvey H, Thompson CB. Overexpression of HER2 modulates bcl-2, bcl-XL, and tamoxifen-induced apoptosis in human MCF-7 breast cancer cells. Clin Cancer Res 1996;2:1215–19
   PubMed Web of Science ®Google Scholar
• Nicholson RI, McClelland RA, Finlay P, et al. Relationship between EGF-R, c-erb B-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity. Eur J Cancer 1993;29A:1018–23
   PubMed Web of Science ®Google Scholar
• Magnani L, Stoeck A, Zhang X, et al. Genome-wide reprogramming of the chromatin landscape underlies endocrine therapy resistance in breast cancer. Proc Natl Acad Sci USA 2013; 110:E1490–9
   PubMed Web of Science ®Google Scholar
• Guo S, Li Y, Tong Q, et al.δEF1 down-regulates ER-α expression and confers tamoxifen resistance in breast cancer. PLoS ONE 2012;7:e52380
   PubMed Web of Science ®Google Scholar
• Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004;18:1926–45
   PubMed Web of Science ®Google Scholar
• Sabatini DM. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 2006;6:729–34
   PubMed Web of Science ®Google Scholar
• Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004;4:335–48
   PubMed Web of Science ®Google Scholar
• Carraway H, Hidalgo M. New targets for therapy in breast cancer: mammalian target of rapamycin (mTOR) antagonists. Breast Cancer Res 2004;6:219–24
   PubMed Web of Science ®Google Scholar
• Sokolosky ML, Stadelman KM, Chappell WH, et al. Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapy. Oncotarget 2011;2:538–50
   PubMed Web of Science ®Google Scholar
• Alers S, Löffler AS, Wesselborg S, Stork B. Role of AMPK-mTOR-Ulk1/2 in the regulation of autophagy: cross talk, shortcuts, and feedbacks. Mol Cell Biol 2012;32:2–11
   PubMed Web of Science ®Google Scholar
• Dobashi Y, Watanabe Y, Miwa C, Suzuki S, Koyama S. Mammalian target of rapamycin: a central node of complex signaling cascades. Int J Clin Exp Pathol 2011;4:476–95
   PubMed Web of Science ®Google Scholar
• Cavazzoni A, Bonelli MA, Fumarola C, et al. Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones. Cancer Letters 2012;323:77–87
   PubMed Web of Science ®Google Scholar
• Ramaswamy B, Lu Y, Teng KY, et al. Hedgehog signaling is a novel therapeutic target in tamoxifen resistant breast cancer aberrantly activated by PI3K/AKT pathway. Cancer Res 2012; 72:5048–59
   PubMed Web of Science ®Google Scholar
• Vilquin P, Villedieu M, Grisard E, et al. Molecular characterization of anastrozole resistance in breast cancer: Pivotal role of the Akt/mTOR pathway in the emergence of de novo or acquired resistance and importance of combining the allosteric Akt inhibitor MK-2206 with an aromatase inhibitor. Int J Cancer 2013;133:1589–602
   PubMed Web of Science ®Google Scholar
• Stebbing J, Filipovic A, Lit LC, et al. LMTK3 is implicated in endocrine resistance via multiple signaling pathways. Oncogene 2012;32:3371–80
   PubMed Web of Science ®Google Scholar
• Wong C, Wang X, Smith D, Reddy K, Chen S. AKT-aro and HER2-aro, models for de novo resistance to aromatase inhibitors; molecular characterization and inhibitor response studies. Breast Cancer Res Treat 2012;134:671–81
   PubMed Web of Science ®Google Scholar
• Molloy CA, May FE, Westley BR. Insulin receptor substrate-1 expression is regulated by estrogen in the MCF-7 human breast cancer cell line. J Biol Chem 2000;275:12565–71
   PubMed Web of Science ®Google Scholar
• Becker MA, Ibrahim YH, Cui X, Lee AV, Yee D. The IGF pathway regulates ERalpha through a S6K1-dependent mechanism in breast cancer cells. Mol Endocrinol 2011;25:516–28
   PubMed Web of Science ®Google Scholar
• Fagan DH, Uselman RR, Sachdev D, Yee D. Acquired resistance to tamoxifen is associated with loss of the type I insulin-like growth factor receptor: implications for breast cancer treatment. Cancer Res 2012;72:3372–80
   PubMed Web of Science ®Google Scholar
• Caldon CE, Sergio CM, Kang J, et al. Cyclin E2 overexpression is associated with endocrine resistance but not insensitivity to CDK2 inhibition in human breast cancer cells. Mol Cancer Ther 2012;11:1488–99
   PubMed Web of Science ®Google Scholar
• Tamura T, Yanai H, Savitsky D, Taniguchi T. The IRF family transcription factors in immunity and oncogenesis. Annu Rev Immunol 2008;26:535–84
   PubMed Web of Science ®Google Scholar
• Aguilar H, Solé X, Bonifaci N, et al. Biological reprogramming in acquired resistance to endocrine therapy of breast cancer. Oncogene 2010;29:6071–83
   PubMed Web of Science ®Google Scholar
• Cutrupi S, Reineri S, Panetto A, et al. Targeting of the adaptor protein Tab2 as a novel approach to revert tamoxifen resistance in breast cancer cells. Oncogene 2012;31:4353–61
   PubMed Web of Science ®Google Scholar
• McBryan J, Theissen SM, Byrne C, et al. Metastatic progression with resistance to aromatase inhibitors is driven by the steroid receptor coactivator SRC-1. Cancer Res 2012;72: 548–59
   PubMed Web of Science ®Google Scholar
• Qin L, Liu Z, Chen H, Xu J. The steroid receptor coactivator-1 regulates twist expression and promotes breast cancer metastasis. Cancer Res 2009;69:3819–27
   PubMed Web of Science ®Google Scholar
• Goel A, Janknecht R. Concerted activation of ETS protein ER81 by p160 coactivators, the acetyltransferase p300 and the receptor tyrosine kinase HER2/Neu. J Biol Chem 2004;279:14909–16
   PubMed Web of Science ®Google Scholar
• McCartan D, Bolger JC, Fagan A, et al. Global characterization of the SRC-1 transcriptome identifies ADAM22 as an ER-independent mediator of endocrine-resistant breast cancer. Cancer Res 2012;72:220–9
   PubMed Web of Science ®Google Scholar